Dupilumab for recalcitrant prurigo nodularis: Case report
Dupilumab is a recombinant fully human monoclonal antibody modulating the signaling of the interleukin (IL)-4 and IL-13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis. We present a case of recalcitrant prurigo nodularis treated off-label with dupilumab.
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Sociedade Portuguesa de Dermatologia e Venereologia,
2022-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |